ABDX - Ticker AI Digest

Abingdon Health Plc 📰 1
Desk Snapshot GO VIP Login
Important AI Risk Notice

Charts, catalyst summaries, AI scores, forecasts and price context are AI-driven and can hallucinate, lag or miss market-changing information.

Not investment advice. Markets can move fast and any trade or allocation decision remains your responsibility.
AI can hallucinate. Summaries, rankings, forecasts and commentary can be wrong, incomplete or misleading.
AI-driven data only. Signals, dates, prices, sentiment and automation outputs may be delayed, estimated or stale.
Always verify externally. Confirm prices, filings, broker notes and trade setup details with independent sources before acting.
Mobile Command Deck
Abingdon Health Plc in one cleaner mobile flow.
Tap straight into the module you want. No sideways tab hunt, just a clean route into charts, news, Today’s AI, and the deeper desks.
ABDX Data 2025-12-04 Preview Mode
Core Deck
Deep Dive Modules

Digested News

Today's Catalysts (ABDX) 1
ABDX 06:01
Abingdon Health Plc
Vesting and Award of Options under LTIP
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
Please provide the text you would like me to summarize. Im ready when you are!
Awards
AI 0
No items for this category on selected date.
Acquisitions 0
No items for this category on selected date.
Agreement 0
No items for this category on selected date.
Approvals 0
No items for this category on selected date.
Authorisation 0
No items for this category on selected date.
Awards 1
ABDX 06:01
Abingdon Health Plc
Vesting and Award of Options under LTIP
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
Please provide the text you would like me to summarize. Im ready when you are!
Awards
BTC 0
No items for this category on selected date.
Blockchain 0
No items for this category on selected date.
Breakthrough 0
No items for this category on selected date.
BuyBack 0
No items for this category on selected date.
Cancellations 0
No items for this category on selected date.
CashOffer 0
No items for this category on selected date.
Collaborate 0
No items for this category on selected date.
ContractWin 0
No items for this category on selected date.
Covid-19 0
No items for this category on selected date.
Deals 0
No items for this category on selected date.
Diamond 0
No items for this category on selected date.
DirectorDealing 0
No items for this category on selected date.
Discovery 0
No items for this category on selected date.
Exceeded 0
No items for this category on selected date.
FCA 0
No items for this category on selected date.
FDA 0
No items for this category on selected date.
Grants 0
No items for this category on selected date.
InvestmentPlan 0
No items for this category on selected date.
JV 0
No items for this category on selected date.
Launch 1
ABDX 06:01
Abingdon Health Plc
Launch of seaweed-based lateral flow housings
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
Abingdon Health plc, a leading developer and manufacturer of rapid diagnostic <mark style="background-color:yellow">test</mark>s, has launched seaweed-based lateral flow test (LFT) housings as a sustainable alternative to traditional plastic housings. This innovation aims to reduce the significant plastic waste generated by the over 2 billion LFTs used annually worldwide. The company has partnered exclusively with Symbio Technologies Ltd (SymbioTex) to supply compostable, bio-based material derived from red seaweed, which can be molded using standard injection techniques. Prototypes have been developed for both standard and mid-stream urine sample formats, including pregnancy tests. The seaweed-based housings maintain the functionality of traditional tests while offering an eco-friendly solution. This initiative aligns with Abingdon Health’s commitment to sustainability and leverages renewable resources without requiring new manufacturing infrastructure. The launch underscores the company’s role in addressing environmental concerns in the med-tech industry.
Launch
Litigation 0
No items for this category on selected date.
NewContract 1
ABDX 06:01
Abingdon Health Plc
c.US$2m multiplex diagnostic test contract win
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
Abingdon Health plc, a leading developer and manufacturer of rapid diagnostic <mark style="background-color:yellow">test</mark>s, has secured a **c.US$2 million contract** with a US-based company for the development, scale-up, and technical transfer of a **semi-quantitative, multiplex lateral flow test system**. The 24-month project will be executed under a Master Service Agreement (MSA) and conducted at Abingdon Health’s Madison, Wisconsin facilities. This win highlights the strength of Abingdon Health’s **Contract Development and Manufacturing Organisation (CDMO)** services, which support customers from concept to commercial success. The contract underscores the company’s expanded U.S. manufacturing capabilities, bolstered by a recent £3.2 million fundraise, and its ability to meet growing demand from U.S.-based clients. Dr. Chris Hand, Executive Chairman, emphasized the value of Abingdon’s dual U.S. and U.K. sites and the versatility of lateral flow technology in measuring multiple analytes semi-quantitatively. The announcement reinforces Abingdon Health’s position as a comprehensive CDMO provider in the med-tech sector.
NewContract
Offers 0
No items for this category on selected date.
Offtake 0
No items for this category on selected date.
Orders 0
No items for this category on selected date.
Partner 0
No items for this category on selected date.
Patents 0
No items for this category on selected date.
Placing 0
No items for this category on selected date.
Positive 0
No items for this category on selected date.
Proposals 0
No items for this category on selected date.
Reports 1
ABDX 13:01
Abingdon Health Plc
Notice of AGM & Publication of 2025 Annual Report
Results 1
ABDX 06:01
Abingdon Health Plc
Final Results
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary of Abingdon Health PLCs Final Results for FY25**
**Overview**
Abingdon Health PLC, a leading developer, manufacturer, and regulatory services provider for rapid diagnostic tests and med-tech, announced its final results for the financial year ended 30 June 2025 (FY25). The company reported significant commercial and operational growth, driven by expanded contract development and manufacturing (CDMO) activities, strategic acquisitions, and geographic expansion.
**Commercial and Operational Highlights**
**CDMO Growth**Secured several large contracts, including
US$2m for sexually transmitted disease tests.
£800,000 UKRI funding for malaria rapid diagnostic tests.
Strategic partnerships with Okos Diagnostics for avian flu tests.
€2m CDMO contract for companion diagnostics with a European biotech firm.
Post-period contracts totaling ~US$4.5m for companion diagnostics and multiplex lateral flow tests.
**Expansion Initiatives**
Acquired CS Lifesciences (regulatory services) for £3.2m in August 2024.
Opened Abingdon Analytical Ltd (analytical services) in Doncaster and a US CDMO site in Madison, Wisconsin.
**Sustainability**Launched seaweed-based lateral flow housings to reduce plastic waste.
**Financial Performance**
**Revenue**£8.6m (FY25) vs. £6.1m (FY24), a 40% increase. Includes £0.16m UKRI grant-funded revenue.
**H2 FY25 Strength**Revenue of £5.5m (vs. £3.7m in H2 FY24) and improved adjusted EBITDA loss of £0.7m (vs. £0.2m loss in H2 FY24).
**Adjusted EBITDA Loss**£2.7m (FY25) vs. £1.2m (FY24), due to growth investments.
**Reported Operating Loss**£3.5m (FY25) vs. £1.4m (FY24), after depreciation, amortization, and one-off items.
**Cash Position**£1.9m at 30 June 2025, supported by £5.2m net proceeds from August 2024 fundraising and £3.2m post-period fundraising.
**Strategic Acquisitions and Integration**
CS Lifesciences acquisition deepened regulatory expertise and expanded into medical devices and software.
Integration progressing well, with a £500k+ contract win extended to over £1m.
**Geographic Expansion**
US CDMO site in Madison operational since April 2025, securing US$2m+ contracts.
Plans to expand US manufacturing capacity post-October 2025 fundraising.
**Product and Technology Development**
Launched seaweed-based lateral flow housings for sustainability.
Patented AI-driven AppDx® technology for commercial use.
**Outlook**
FY26 started strongly, with Q1 revenue significantly ahead of prior period.
Focus on revenue growth, cost control, and progression toward profitability and cashflow positivity by 2026.
Continued expansion in the US and execution of larger contracts.
**Leadership and Governance**
Appointed Tom Hayes as CFO in January 2025 and Dr. Katie Brenner as Non-Executive Director in April 2025.
Chris Hand continues as Executive Chairman, and Chris Yates focuses on commercial growth as President of Abingdon Health USA Inc.
**Conclusion**
Abingdon Health demonstrated robust growth in FY25, driven by strategic acquisitions, CDMO expansion, and geographic diversification. Despite increased investment-related losses, the company is well-positioned for FY26, with a strong pipeline and focus on profitability and cashflow improvement.
Here’s an HTML table comparing the financials and debt year-on-year for Abingdon Health PLC based on the provided text:
MetricFY2024 (£'000)FY2025 (£'000)Change (£'000)Change (%)
Revenue6,1358,4292,29437.4%
Gross Profit3,6793,736571.5%
Operating Loss(1,373)(3,509)(2,136)-155.6%
Adjusted EBITDA Loss(1,132)(2,586)(1,454)-128.4%
Cash at Bank and in Hand1,4401,91847833.2%
Total Debt (Borrowings)722745233.2%
### Key Notes: 1. **Revenue**: Increased by 37.4% from £6.135m in FY2024 to £8.429m in FY2025, driven by growth in CDMO activities and new contracts. 2. **Gross Profit**: Marginal increase of 1.5%, with a decrease in gross profit margin due to the acquisition of CS Lifesciences and changes in revenue mix. 3. **Operating Loss**: Widened significantly by 155.6% due to increased investment in growth initiatives and higher administrative expenses. 4. **Adjusted EBITDA Loss**: Increased by 128.4% due to higher investment in operations and expansion. 5. **Cash at Bank and in Hand**: Increased by 33.2% due to successful fundraisings in August 2024 and October 2025. 6. **Total Debt**: Increased slightly by 3.2%, primarily due to borrowings and lease liabilities. This table provides a clear comparison of key financial metrics and debt levels between FY2024 and FY2025.
Significant 0
No items for this category on selected date.
Speculation 0
No items for this category on selected date.
Strategic 0
No items for this category on selected date.
Suspension 0
No items for this category on selected date.
TR1 3
ABDX 14:09
Abingdon Health Plc
Holding(s) in Company
ABDX 15:59
Abingdon Health Plc
Holding(s) in Company
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
TR1 Buy
ABDX 06:01
Abingdon Health Plc
Holding(s) in Company
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
TR1 Buy
Takeover 0
No items for this category on selected date.
Understanding 0
No items for this category on selected date.
Updates 0
No items for this category on selected date.
Vaccine 0
No items for this category on selected date.
Wins 0
No items for this category on selected date.
Worth 0
No items for this category on selected date.
All Market News (Last 30 Days) 8
ABDX 06:01
Abingdon Health Plc
Vesting and Award of Options under LTIP
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
Please provide the text you would like me to summarize. Im ready when you are!
Awards
ABDX 14:09
Abingdon Health Plc
Holding(s) in Company
ABDX 13:01
Abingdon Health Plc
Notice of AGM & Publication of 2025 Annual Report
ABDX 06:01
Abingdon Health Plc
Final Results
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary of Abingdon Health PLCs Final Results for FY25**
**Overview**
Abingdon Health PLC, a leading developer, manufacturer, and regulatory services provider for rapid diagnostic tests and med-tech, announced its final results for the financial year ended 30 June 2025 (FY25). The company reported significant commercial and operational growth, driven by expanded contract development and manufacturing (CDMO) activities, strategic acquisitions, and geographic expansion.
**Commercial and Operational Highlights**
**CDMO Growth**Secured several large contracts, including
US$2m for sexually transmitted disease tests.
£800,000 UKRI funding for malaria rapid diagnostic tests.
Strategic partnerships with Okos Diagnostics for avian flu tests.
€2m CDMO contract for companion diagnostics with a European biotech firm.
Post-period contracts totaling ~US$4.5m for companion diagnostics and multiplex lateral flow tests.
**Expansion Initiatives**
Acquired CS Lifesciences (regulatory services) for £3.2m in August 2024.
Opened Abingdon Analytical Ltd (analytical services) in Doncaster and a US CDMO site in Madison, Wisconsin.
**Sustainability**Launched seaweed-based lateral flow housings to reduce plastic waste.
**Financial Performance**
**Revenue**£8.6m (FY25) vs. £6.1m (FY24), a 40% increase. Includes £0.16m UKRI grant-funded revenue.
**H2 FY25 Strength**Revenue of £5.5m (vs. £3.7m in H2 FY24) and improved adjusted EBITDA loss of £0.7m (vs. £0.2m loss in H2 FY24).
**Adjusted EBITDA Loss**£2.7m (FY25) vs. £1.2m (FY24), due to growth investments.
**Reported Operating Loss**£3.5m (FY25) vs. £1.4m (FY24), after depreciation, amortization, and one-off items.
**Cash Position**£1.9m at 30 June 2025, supported by £5.2m net proceeds from August 2024 fundraising and £3.2m post-period fundraising.
**Strategic Acquisitions and Integration**
CS Lifesciences acquisition deepened regulatory expertise and expanded into medical devices and software.
Integration progressing well, with a £500k+ contract win extended to over £1m.
**Geographic Expansion**
US CDMO site in Madison operational since April 2025, securing US$2m+ contracts.
Plans to expand US manufacturing capacity post-October 2025 fundraising.
**Product and Technology Development**
Launched seaweed-based lateral flow housings for sustainability.
Patented AI-driven AppDx® technology for commercial use.
**Outlook**
FY26 started strongly, with Q1 revenue significantly ahead of prior period.
Focus on revenue growth, cost control, and progression toward profitability and cashflow positivity by 2026.
Continued expansion in the US and execution of larger contracts.
**Leadership and Governance**
Appointed Tom Hayes as CFO in January 2025 and Dr. Katie Brenner as Non-Executive Director in April 2025.
Chris Hand continues as Executive Chairman, and Chris Yates focuses on commercial growth as President of Abingdon Health USA Inc.
**Conclusion**
Abingdon Health demonstrated robust growth in FY25, driven by strategic acquisitions, CDMO expansion, and geographic diversification. Despite increased investment-related losses, the company is well-positioned for FY26, with a strong pipeline and focus on profitability and cashflow improvement.
Here’s an HTML table comparing the financials and debt year-on-year for Abingdon Health PLC based on the provided text:
MetricFY2024 (£'000)FY2025 (£'000)Change (£'000)Change (%)
Revenue6,1358,4292,29437.4%
Gross Profit3,6793,736571.5%
Operating Loss(1,373)(3,509)(2,136)-155.6%
Adjusted EBITDA Loss(1,132)(2,586)(1,454)-128.4%
Cash at Bank and in Hand1,4401,91847833.2%
Total Debt (Borrowings)722745233.2%
### Key Notes: 1. **Revenue**: Increased by 37.4% from £6.135m in FY2024 to £8.429m in FY2025, driven by growth in CDMO activities and new contracts. 2. **Gross Profit**: Marginal increase of 1.5%, with a decrease in gross profit margin due to the acquisition of CS Lifesciences and changes in revenue mix. 3. **Operating Loss**: Widened significantly by 155.6% due to increased investment in growth initiatives and higher administrative expenses. 4. **Adjusted EBITDA Loss**: Increased by 128.4% due to higher investment in operations and expansion. 5. **Cash at Bank and in Hand**: Increased by 33.2% due to successful fundraisings in August 2024 and October 2025. 6. **Total Debt**: Increased slightly by 3.2%, primarily due to borrowings and lease liabilities. This table provides a clear comparison of key financial metrics and debt levels between FY2024 and FY2025.
ABDX 06:01
Abingdon Health Plc
c.US$2m multiplex diagnostic test contract win
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
Abingdon Health plc, a leading developer and manufacturer of rapid diagnostic <mark style="background-color:yellow">test</mark>s, has secured a **c.US$2 million contract** with a US-based company for the development, scale-up, and technical transfer of a **semi-quantitative, multiplex lateral flow test system**. The 24-month project will be executed under a Master Service Agreement (MSA) and conducted at Abingdon Health’s Madison, Wisconsin facilities. This win highlights the strength of Abingdon Health’s **Contract Development and Manufacturing Organisation (CDMO)** services, which support customers from concept to commercial success. The contract underscores the company’s expanded U.S. manufacturing capabilities, bolstered by a recent £3.2 million fundraise, and its ability to meet growing demand from U.S.-based clients. Dr. Chris Hand, Executive Chairman, emphasized the value of Abingdon’s dual U.S. and U.K. sites and the versatility of lateral flow technology in measuring multiple analytes semi-quantitatively. The announcement reinforces Abingdon Health’s position as a comprehensive CDMO provider in the med-tech sector.
NewContract
ABDX 06:01
Abingdon Health Plc
Launch of seaweed-based lateral flow housings
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
Abingdon Health plc, a leading developer and manufacturer of rapid diagnostic <mark style="background-color:yellow">test</mark>s, has launched seaweed-based lateral flow test (LFT) housings as a sustainable alternative to traditional plastic housings. This innovation aims to reduce the significant plastic waste generated by the over 2 billion LFTs used annually worldwide. The company has partnered exclusively with Symbio Technologies Ltd (SymbioTex) to supply compostable, bio-based material derived from red seaweed, which can be molded using standard injection techniques. Prototypes have been developed for both standard and mid-stream urine sample formats, including pregnancy tests. The seaweed-based housings maintain the functionality of traditional tests while offering an eco-friendly solution. This initiative aligns with Abingdon Health’s commitment to sustainability and leverages renewable resources without requiring new manufacturing infrastructure. The launch underscores the company’s role in addressing environmental concerns in the med-tech industry.
Launch
ABDX 15:59
Abingdon Health Plc
Holding(s) in Company
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
TR1 Buy
ABDX 06:01
Abingdon Health Plc
Holding(s) in Company
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
TR1 Buy

Today's AI

Today's AI Starts With News

1 live catalyst is opening Today’s AI for ABDX.

Start with the live headline tape first. Today’s AI findings sit next, and the AI Blend stack drops lower once the news context is framed. Financial Forecastist now feeds the blend too.
Live Tape Data 2025-12-04 Blend Lower Down
Read the alert tape first, then open Today’s AI findings. Use AI Expand on any card to open the AI explanation, results tables and financial forecast rows instantly.
1 Today
Front Of Desk
Abingdon Health Plc has fresh news flow live now, so Today’s AI is leading with the tape before the blended signal stack below.
Single-Ticker Today's AI
ABDX signal theatre built from scored market catalysts, automated AI forecasts, financial forecasting and live trigger logic.

This is the ticker-specific Today’s AI desk for Abingdon Health Plc. It compresses the live catalyst tape, bullish and bearish scoring, AI price forecasts, financial forecasting and trigger logic into one cockpit so users can judge conviction without hopping across screens.

Subscription Required Bullish vs Bearish Scoring AI + Financial Blend Buy / Sell Trigger Engine Today's AI Findings
Create Account Member Login
Subscriber Unlock
Subscribe to unlock the full ABDX Today’s AI cockpit.

Subscription turns this tab into a live signal desk with today’s news findings at the top, AI plus financial blend comparisons at the bottom, buy and sell trigger logic, and the full findings ledger behind every scored row.

  • AI-scored market headlines with sentiment buckets and buzzword breakdowns.
  • Forecast leaders ranked by projected gain against current market price.
  • Advanced technical scans, AI forecast stacks, and predictive MACD inside the live stock terminal charts.
  • Single-ticker AI Crunch desks with buy or sell trigger logic and full catalyst ledgers.
  • Scored earnings shock board with predicted direction, sector pulse and catalyst narrative.
  • Fast market scan built for event-driven trading, not passive dashboards.
Subscribe to unlock the ticker-specific Today’s AI stack, sentiment gauges, AI blend stage, and the full findings ledger for ABDX on 2025-12-04.

Fundamentals Matrix

Overall Fundamentals
Signal: Pending
Capital Strength
Signal: Pending
Float Liquidity
Signal: Pending
Short Pressure
Signal: Pending
Target Setup
Signal: Pending
Market Profile
Signal: Pending
Market Cap
32.6M
Enterprise Value
4.2M
Public Float
66.8
Broker Target
19
Shares Out
251.1M
Long Interest
0
Short Interest
0
Exchange
LSE
Currency Code
GBX
ISIN
GB00BLF79J41
Market
LSE - AIM
Sector
Medical Equipment and Services
Float / Shares Ratio
-
Short vs Long Delta
-
EV / Market Cap
-

Financials Matrix

News And Alerts First

1 live alert now opens the financials desk for ABDX.

Start with the headline flow and alert tape first. Then drop straight into Financial Forecastist below for the revenue path, EPS shape, cash pressure and balance-sheet read while the catalyst context is still hot.
Live Alerts Data 2025-12-04 Forecastist Below
Read the alert tape first, then move into Financial Forecastist below. Use AI Expand on any catalyst card to open the AI explanation and results tables without losing the ticker context.
1 Alerts
Front Of Desk
Abingdon Health Plc has fresh filing flow live now, so the tape is framing the revenue, leverage and valuation story below.
Overall Stability
Signal: Pending
Profitability
Signal: Pending
Debt & Cash
Signal: Pending
Valuation Risk
Signal: Pending
Forward Expectation
Signal: Pending
Dividend Safety
Signal: Pending
Divi Rate
-
Ex Divi
2009-01-01
Earnings Date
2026-04-01
Net Debt
-890.0K
Cash
1.9M
EPS
-0.01
Net Income
-3.4M
Revenue
8.4M
Enterprise Value
4.2M
Trailing PE
-
Forward PE
80
Price Sales TTM
3.41
Price Book MRQ
4.7817
EV Revenue
2.8594
EV EBITDA
-0.2499
Financial Forecastist

Improving financial engine

Revenue is accelerating +75.8% against the prior comparable period. Net margin is compressing by 5.4 pts. Net debt is building +178.7%.

Revenue +75.8% Net Income +94.9% FCF +7.5% Current Ratio 1.91x Forward Rev 0
Improving
Quarter Revenue
4.2M
+75.8%
vs prior comparable quarter
Net Margin
-55.4%
-5.4 pts
profitability pulse
Free Cash Flow
-1.3M
+7.5%
cash conversion
Net Debt / EBITDA
1.1x
+178.7%
lower is cleaner
Revenue Engine

Latest quarter printed 4.2M with the top line pushing higher against the last comparable period.

Profit Stack

Net income landed at -2.3M and the margin profile is tightening. That usually tells us whether operating leverage is finally kicking in.

Balance-Sheet Pressure

Cash sits near 3.7M while net debt is -2.8M. The leverage stack is moving the wrong way.

Quarterly Revenue Runway

Actual revenue bars, consensus revenue where available, plus the terminal model path.

Profit And Cash Conversion

Net income and free cash flow moving together is usually what separates genuine improvement from noise.

Balance-Sheet Pressure

Cash, net debt and liquidity tell us whether the business is strengthening or just surviving.

Annual Power Curve

Longer-cycle revenue and net income help frame whether the company is compounding or rolling over.
Q4 2023
Consensus
0
Revenue Path
0.00
EPS / Earnings
Growth cue -
Q1 2024
Consensus
0
Revenue Path
0.00
EPS / Earnings
Growth cue -
Q3 2024
Consensus
0
Revenue Path
0.00
EPS / Earnings
Growth cue -
Q4 2024
Consensus
0
Revenue Path
0.00
EPS / Earnings
Growth cue -
FY 2026
Consensus
12.2M
Revenue Path
-0.00
EPS / Earnings
Growth cue +0.9%
FY 2027
Consensus
15.2M
Revenue Path
0.00
EPS / Earnings
Growth cue +1.6%

Quarterly Statement Tape

Last 6 Quarters
Period Revenue Net Income FCF Net Debt
Q4 2025 4.2M -2.3M -1.3M -2.8M
Q2 2025 5.3M -894.0K -1.3M -890.0K
Q4 2024 3.1M -2.5M -2.2M -2.7M
Q2 2024 3.7M -66.0K -477.0K -391.0K
Q4 2023 2.4M -1.2M -1.2M -990.0K
Q2 2023 2.9M -1.0M -1.1M -2.2M

Annual Financial Power

Last 5 Years
Period Revenue Net Income EBITDA FCF
FY 2025 8.4M -3.4M -3.1M -3.4M
FY 2024 6.1M -1.3M -916.0K -1.7M
FY 2023 4.0M -3.5M -2.8M 845.0K
FY 2022 2.8M -21.3M -20.0M -8.5M
FY 2021 11.6M -7.0M -6.1M -20.1M

Structure DNA

Market Structure DNA has not been loaded for this ticker yet. Once the A15 loader runs, this desk will light up with regime labels, ownership lock, dividend cadence, and structure charts.

Capital Radar

Capital Regime
—
Building signal blend...
Smart Money Tilt
—
Public vs institutions
Target Conviction
—
Broker coverage pulse
Insider Pressure
—
Director + TR1 flow
Last Held Position
-
Public Hands
-
Institutions
44.9753
Institutions As Of
2025-11-04
Avg Broker Target
-
Upside Vs Price
-
Purchase Director Dealing
0
Sale Director Dealing
0
Purchase TR1
6
Sale TR1
1
Broker Coverage Rows
0
Institution Holders Tracked
5
Public Vs Institutional Ownership (3D)
Top Institution Holders (Latest Per Holder)
Director Dealing Sentiment Flow
Broker Target Bias
Signal: Pending
Capital Momentum Matrix
Broker Targets Vs Price
Aggregated Institution Weight By Holder

Short Data - Last 30 Days

Nexus Pulse Engine

Overall Buy/Sell/Hold
Signal: Pending
Technical Composite
Signal: Pending
Financial Composite
Signal: Pending
Fundamental Composite
Signal: Pending
Short Pressure
Signal: Pending
Momentum Bias
Signal: Pending

Volatility Lab

ATR(14)
Realized Vol (20d)
Volume Spike Z

AI Charts

News And Alerts First

The alert tape opens the door for ABDX, and AI Charts sits just below.

Start with the headline flow and live catalyst tape first. Then move straight into AI Charts below for price reaction, AI targets, chart structure and catalyst beacons while the news context is still hot.
Live Tape Data 2025-12-04 AI Charts Below
Read the alert tape first, then move into AI Charts below. Use AI Expand on any catalyst card to open the AI explanation and results tables instantly.
1 Today
Catalyst Pulse
Abingdon Health Plc has fresh news flow live now, so the tape is framing the chart workspace below.
AI Charts Studio
ABDX Price History
Live structure, automated forecasts, technical overlays and catalyst beacons in one chart workspace.
30 Day View Window 30D Data 2025-12-04 Open Preview Studio Brief
Chart Intelligence Suite
Swipe the timeframe, call the overlays, and keep the AI signal stack fused into one chart cockpit.
The mobile chart console is now framed as one connected surface so forecasting, structure, catalyst beacons and chart tools all sit inside the price workspace.

Automated signalling scans momentum shifts, crossovers and volatility breaks in real time. Automated AI forecasts map best, average and worst simulation paths forward, predictive MACD extends the momentum story, and catalyst beacons pin market-moving headlines directly onto price action so users can connect news, signals and structure without leaving the chart.

Automated Signalling Automated AI Forecasts Predictive MACD Catalyst Beacons Live Price Structure
Desk Snapshot Member Login
Indicators0
Technicals0
AI Forecast 121.04%
RSI Gauge
Price Change
AI Forecast